Lamivudine
-
{
- All
- News
-
USFDA Gives Nod To Lupin To Market HIV Treatment Tablets
Pharma major Lupin has received tentative approval for its Abacavir Sulfate and Lamivudine tablets from the USFDA to market generic version of ViiV Healthcare company's Epzicom tablets.
-
Strides Arcolab's HIV Treatment Drug Gets US Regulator's Nod
The drug belongs to a group of anti-viral medicines, also known as anti-retrovirals, and is used with other anti-retroviral medicines to treat HIV infection in adults and children.
-
Lupin Gets US Regulator's Nod for HIV Drug
Drug major Lupin has received approval of the US Food and Drug Administration (FDA) to market a generic version of ViiV Healthcare's 'Epivir' tablets, used in treating HIV infection, in the American market. Shares in Lupin rose nearly 1 per cent during the day.
-
WHO approves AIDS drug combination
The World Health Organisation has approved the use of a three-in-one combination AIDS treatment pill under a new plan to rush antiretroviral (ARV) medicines to three million people in developing countries.
-
USFDA Gives Nod To Lupin To Market HIV Treatment Tablets
Pharma major Lupin has received tentative approval for its Abacavir Sulfate and Lamivudine tablets from the USFDA to market generic version of ViiV Healthcare company's Epzicom tablets.
-
Strides Arcolab's HIV Treatment Drug Gets US Regulator's Nod
The drug belongs to a group of anti-viral medicines, also known as anti-retrovirals, and is used with other anti-retroviral medicines to treat HIV infection in adults and children.
-
Lupin Gets US Regulator's Nod for HIV Drug
Drug major Lupin has received approval of the US Food and Drug Administration (FDA) to market a generic version of ViiV Healthcare's 'Epivir' tablets, used in treating HIV infection, in the American market. Shares in Lupin rose nearly 1 per cent during the day.
-
WHO approves AIDS drug combination
The World Health Organisation has approved the use of a three-in-one combination AIDS treatment pill under a new plan to rush antiretroviral (ARV) medicines to three million people in developing countries.
